Abstract
Pancreatic neuroendocrine tumours (pNETs) are relatively rare and generally felt to follow an indolent course. But poorly differentiated tumours can behave aggressively with 5-year survival ranging from 31% to 48%. Recent data suggest that patients with pNETs may derive benefit from treatment targeting the molecular changes expressed in this tumour group. This article describes advances in the treatment of unresectable pNETs that have led to a doubling of progression free survival.
MeSH terms
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Disease-Free Survival
-
Everolimus
-
Humans
-
Indoles / pharmacology
-
Indoles / therapeutic use
-
Neuroendocrine Tumors / drug therapy*
-
Pancreatic Neoplasms / drug therapy*
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use
-
Randomized Controlled Trials as Topic
-
Sirolimus / analogs & derivatives
-
Sirolimus / pharmacology
-
Sirolimus / therapeutic use
-
Sunitinib
Substances
-
Antineoplastic Agents
-
Indoles
-
Pyrroles
-
Everolimus
-
Sunitinib
-
Sirolimus